Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of inpatient electroencephalography on clinical decision making.

The Journal of the American Osteopathic Association·2013

Same author

Effect of vitamin D replacement on insulin sensitivity in subjects with vitamin D deficiency.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2012

Same author

Common patient concerns about the use of glucagon-like peptide-1 receptor agonists in diabetes mellitus management.

The Journal of the American Osteopathic Association·2012

Same author

Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.

The Journal of the American Osteopathic Association·2012

Same author

Diabetes--it's the basics that count.

The Journal of the American Osteopathic Association·2011

Same author

Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.

The Journal of the American Osteopathic Association·2011

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Lepr^db Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Islet cell dysfunction in progression to diabetes mellitus.

Craig W Spellman¹

¹Division of Endocrinology at the University of North Texas Health Science Center at Fort Worth-Texas College of Osteopathic Medicine, USA. cspellma@hsc.unt.edu

The Journal of the American Osteopathic Association

|September 19, 2007

Summary

Type 2 diabetes is rising globally, causing severe complications. New therapies are needed to address abnormal glucose metabolism by understanding beta-cell function and alpha-cell regulation.

More Related Videos

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice

Published on: April 10, 2026

Related Experiment Videos

Last Updated: Jul 12, 2026

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Lepr^db Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice

Published on: April 10, 2026

Area of Science:

Endocrinology and Metabolism
Diabetes Research
Molecular Medicine

Background:

The global epidemic of type 2 diabetes mellitus (T2DM) is increasing, posing significant public health challenges.
T2DM is a leading cause of severe long-term complications, including cardiovascular disease, stroke, blindness, renal failure, and amputations.
Current therapeutic interventions for T2DM often lack durability, necessitating the development of novel treatment strategies.

Purpose of the Study:

To investigate the underlying causes of abnormal glucose metabolism in type 2 diabetes.
To elucidate the mechanisms of beta-cell compensation for insulin resistance and the reasons for beta-cell failure.
To explore therapeutic strategies targeting alpha-cell dysregulation and its impact on hepatic glucose production.

Main Methods:

This study requires further investigation into beta-cell mass dynamics and insulin secretion.
Analysis of alpha-cell function and glucagon suppression is crucial.
Exploration of novel therapeutic targets for glucose metabolism.

Main Results:

Beta-cell mass compensation for insulin resistance is a critical factor in T2DM pathogenesis.
Understanding the mechanisms of beta-cell failure is essential for developing effective therapies.
Alpha-cell dysregulation contributes to hyperglycemia through impaired glucagon suppression.

Conclusions:

New therapeutic approaches for T2DM must target the root causes of abnormal glucose metabolism.
Further research into beta-cell and alpha-cell biology is vital for advancing T2DM treatment.
Addressing both beta-cell dysfunction and alpha-cell dysregulation offers a promising avenue for durable T2DM management.